Sanofi Ousts CEO, Acquires Dynavax for $2.2B
Pharmaceutical giant Sanofi has ousted CEO Paul Hudson amid challenges in vaccine development and slow growth, naming the outgoing CEO of Merck as his surprise replacement. In a move to bolster its pipeline, Sanofi also completed its $2.2 billion acquisition of Dynavax, gaining access to vaccine and immunotherapy assets.
- Paul Hudson's departure follows a series of research and development setbacks, including failures in late-stage trials for potential blockbuster drugs. This increased pressure on Sanofi to strengthen its pipeline as its top-selling anti-inflammatory drug, Dupixent, faces loss of market exclusivity in the next decade. - The incoming CEO, Belén Garijo, has been the CEO of Merck KGaA since 2021, where she was the first woman to lead a major German blue-chip company. This marks a return for Garijo, who previously spent 15 years at Sanofi and notably oversaw the integration of Genzyme. - The Dynavax acquisition is centered on its adult hepatitis B vaccine, HEPLISAV-B, which is administered in two doses over one month. This offers faster protection compared to the traditional three-dose vaccines given over six months. - Through the acquisition, Sanofi also gains a promising shingles vaccine candidate, Z-1018, which is currently in Phase 1/2 clinical trials and could eventually compete with GSK's market-leading shot, Shingrix. - The purchase helps bolster Sanofi's adult vaccine unit, which has been heavily dependent on influenza shots and recently reported slipping sales. - The abrupt nature of Hudson's removal contrasts with recent, longer leadership transitions at other major European pharmaceutical companies like GSK and Novo Nordisk. - During Hudson's six-year tenure, Sanofi's stock price remained largely unchanged, significantly underperforming European rivals like AstraZeneca and GSK, whose investors saw returns of 133% and 65% respectively over the same period. - Following the announcement of the leadership change, Sanofi's shares fell by approximately 5%, indicating initial investor skepticism.
